Open AccessLimited Benefit of Biochemical Response to Combination Therapy for Patients With Recurrent Hepatitis C After Living-Donor Liver Transplantation
Author(s) -
Yoshihide Ueda,
Yasutsugu Takada,
Hironori Haga,
Motoshige Nabeshima,
Hiroyuki Marusawa,
Takashi Ito,
Hiroto Egawa,
Kôichi Tanaka,
Shinji Üemoto,
Tsutomu Chiba
Publication year - 2008
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e3181671df0
Subject(s) - medicine , ribavirin , gastroenterology , combination therapy , fibrosis , liver transplantation , transplantation , stage (stratigraphy) , hepatitis c , alanine aminotransferase , hepatitis , immunology , hepatitis c virus , virus , biology , paleontology
Effective management of patients with recurrent hepatitis C after liver transplantation has not been established. In this study, we tested the significance of biochemical response (BR) as well as sustained virological response (SVR) to combination therapy with interferon alpha-2b and ribavirin for recurrent hepatitis C after living-donor liver transplantation.